AstraZeneca reported Tuesday that its BTK contender Calquence (acalabrutinib) aced a Phase III trial as a second-line therapy for chronic lymphocytic leukemia patients, allowing researchers to call it early as they position this drug for greener pastures.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,